本文選題：尼莫地平注射液 + 參附注射液　； 參考：《中國臨床藥理學(xué)雜志》2017年19期

【摘要】：目的觀察創(chuàng)傷性蛛網(wǎng)膜下腔出血用于尼莫地平注射液聯(lián)合參附注射液的臨床療效。方法將84例創(chuàng)傷性蛛網(wǎng)膜下腔出血患者隨機分為對照組與試驗組,每組42例。對照組給予尼莫地平注射液20 mg,qd,靜脈滴注;試驗組在對照組的基礎(chǔ)上給予參附注射液30 mL+5%葡萄糖注射液250 m L,bid,靜脈滴注。2組均連續(xù)用藥14 d。比較2組患者的臨床療效、炎癥因子水平、凝血功能及藥物不良反應(yīng)發(fā)生情況。結(jié)果治療后,試驗組預(yù)后良好率為69.05%(29/42例),對照組為47.62%(20/42例),差異有統(tǒng)計學(xué)意義(P0.05)。試驗組白細胞介素-6(IL-6)、腫瘤壞死因子-α(TNF-α)、凝血酶原時間、部分凝血活酶時間分別為(0.85±0.11)μg·L~(-1),(0.57±0.07)μg·L~(-1),(12.40±1.66)s,(33.75±3.88)s,對照組分別為(1.06±0.15)μg·L~(-1),(1.06±0.13)μg·L~(-1),(14.69±1.63)s,(36.69±4.44)s,差異均有統(tǒng)計學(xué)意義(P0.05)。對照組出現(xiàn)腦梗死4例,腦積水2例,腦出血6例,腦血管痙攣6例,藥物不良反應(yīng)率為42.86%(18/42例);試驗組出現(xiàn)腦梗死和腦積水各1例,腦出血和腦血管痙攣各2例,藥物不良反應(yīng)率為14.28%(6/42例),差異有統(tǒng)計學(xué)意義(P0.05)。結(jié)論尼莫地平注射液聯(lián)合參附注射液用于創(chuàng)傷性蛛網(wǎng)膜下腔出血的臨床效果較好,能夠利于患者預(yù)后,改善炎癥反應(yīng)及凝血功能。
[Abstract]:Objective to observe the clinical effect of Nimodipine injection combined with Shenfu injection on traumatic subarachnoid hemorrhage. Methods 84 patients with traumatic subarachnoid hemorrhage were randomly divided into control group and experimental group with 42 cases in each group. The control group was given nimodipine injection 20 mg / g QD, and the experimental group was given Shenfu injection 30 mL 5% glucose injection 250 mL / L bid for 14 days. The clinical efficacy, inflammatory factor level, coagulation function and adverse drug reaction were compared between the two groups. Results after treatment, the good prognosis rate of the trial group was 69.05 / 29 / 42 cases, while that of the control group was 47.622% 20 / 42 cases. The difference was statistically significant (P 0.05). 璇曢獙緇勭櫧緇嗚優(yōu)浠嬬礌-6(IL-6),鑲跨槫鍧忔鍥犲瓙-偽(TNF-偽),鍑濊閰跺師鏃墮棿,閮ㄥ垎鍑濊媧婚叾鏃墮棿鍒嗗埆涓，

本文編號：1882150